EU Commission To End AstraZeneca, Johnson & Johnson Vaccine Contracts At Expiry: Report

Brussels would rather focus on COVID-19 vaccines using messenger RNA (mRNA) technology, such as Pfizer's and Moderna's, Italian daily La Stampa reported on Wednesday, citing a source from the Italian health ministry.

The EU Commission has decided not to renew COVID-19 vaccine contracts next year with AstraZeneca and Johnson & Johnson (J&J), Italian daily La Stampa reported on Wednesday, citing a source from the Italian health ministry. "The European Commission, in agreement with the leaders of many (EU) countries, has decided that the contracts with the companies that produce (viral vector) vaccines that are valid for the current year will not be renewed at their expiry," the newspaper reported. It added that Brussels would rather focus on COVID-19 vaccines using messenger RNA (mRNA) technology, such as Pfizer's and Moderna's. A spokesman for the EU Commission said it was keeping all options open to be prepared for the next stages of the pandemic, for 2022 and beyond.